country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P9932

Copy Link Print Information

Obiltoxaximab

(Synonyms: ETI 204)

고객리뷰

Based on 1 Customer Validation

Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.06%
CAS No.: 1351337-07-9
분자량:145.5 kDa

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Obiltoxaximab Chemical Structure

CAS No.: 1351337-07-9

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- 신청
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

anthrax protective antigen

In Vivo

Obiltoxaximab (16 mg/kg, i.v., a single dose for 70 days) for simulated populations of healthy and infected humans is comparable in overall serum exposures in individual infected macaques following obiltoxaximab, similar results in rabbit experiments^[1].
Obiltoxaximab (16 mg/kg, i.m., 24, 48, 72 h prior to lethal challenge with B. anthracis spores) leads to 100% survival challenged with B. anthracis spores in cynomolgus macaques and prevents systemic bacteremia in the vast majority of animals^[2].
Obiltoxaximab (4 and 8 mg/kg, i.v. and i.m., a single dose for 9 h) postexposure prophylaxis (PEP) leads to 100% survival with the combination of Levofloxacin (HY-B0330) challenged with B. anthracis spores in rabbits^[2].
Obiltoxaximab (8 mg/kg, i.v., a single dose, 29 days) combined with antibiotics or Doxycycline (HY-N0565) lowers bacteremia levels in protective antigen (PA) of anthrax induced rabbits^[5].

Pharmacokinetics of intramuscular Obiltoxaximab^[2]

Study and dose (mg/kg)	Postchallenge dosing schedule	C_max (μg/mL)	T_max (days)	AUC_0-∞ (μg·day/mL)	T_1/2 (days)	CL /F(mL/day/kg)	V_z/F (mL/kg)
PEP 2
8	18 h	80.8	1.0	1030	7.50	7.76	84.0
8	24 h	86.5	1.0	788	5.20	10.2	76.2
16	18 h	165	1.0	2120	8.44	7.54	91.9
16	24 h	119	1.0	1990	9.85	8.03	114
PEP 3
16	24 h	142	1.0	2190	10.4	7.00	110
16	36 h	132	0.50	1540	7.09	10.0	106
16	48 h	104	3.0	2040	12.6	8.00	143

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Human, macaques and rabbits^[1]
Dosage:

16 mg/kg
Administration:

i.v., a single dose, 70 days
Result:

Overall serum exposures were comparable following obiltoxaximab in human, macaques and rabbits.

Animal Model:

Cynomolgus macaques^[2]
Dosage:

16 mg/kg
Administration:

i.m., 24, 48, 72 h prior to lethal challenge with B. anthracis spores
Result:

Resulted in transient low levels of bacteremia in several animals, resolving in all animals after day 4, and the majority of animals remained abacteremic until day 56.

Animal Model:

Rabbits^[2]
Dosage:

4 and 8 mg/kg
Administration:

i.v. and i.m. at 4 and 8 mg/kg, a single dose, 9 h
Result:

Effectiveness in the PEP setting was initially examined in rabbits.

Animal Model:

Protective antigen (PA) of anthrax induced rabbits^[5]
Dosage:

8 mg/kg
Administration:

i.v., a single dose, 29 days
Result:

Lowered bacteremia levels between days 1 and 2 combined with antibiotics, eliminated bacteremia levels combined with Doxycycline (HY-N0565) in protective antigen (PA) of anthrax induced rabbits.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

45025512 [NCBI]

Accession

P13423

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

신청

ELISA, FACS, Functional assay

Chemical Information

CAS No. 1351337-07-9
Appearance Liquid
분자량 145.5 kDa
Color Colorless to light yellow
SMILES

[Obiltoxaximab]
Synonyms

ETI 204
선적

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (266 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Nagy CF, et al. Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule. Clin Transl Sci. 2017 Jan;10(1):12-19. [Content Brief]

[2]. Yamamoto BJ, et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5796-805. [Content Brief]

[3]. Hou A W, et al. Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection[J]. Annals of Pharmacotherapy, 2017, 51(10): 908-913. [Content Brief]

[4]. Yamamoto B J, et al. Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre-and postexposure prophylaxis in animal models of inhalational anthrax[J]. Antimicrobial agents and chemotherapy, 2016, 60(10): 5796-5805. [Content Brief]

[5]. Biron B, et al. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax[J]. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- 신청
Chemical Information
순도&문서
References

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Obiltoxaximab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Antibody Inhibitor Library

Biological Activity

Chemical Information

순도&문서

References

Calculators

Help & FAQs

Obiltoxaximab Related Classifications

HY-P9932 Related Classifications